



## EDCTP Stakeholder Meeting Tuberculosis and mycobacterial infections

Monday 28 – Tuesday 29 October 2013  
Fondation del Duca  
Le Grand Salon room  
10 rue Alfred de Vigny – 75008 Paris, France

### Monday 28 October 2013

09:00-10:00	Registration
10:00-10:15	<b>Opening addresses</b> <b>Professor Jean-François Delfraissy</b> , Director of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) <b>Professor Charles Mgone</b> , EDCTP Executive Director
10:15-10:30	<b>Introduction by Chairpersons</b> <b>Professor Hazel Dockrell</b> , London School of Hygiene and Tropical Medicine, (LSHTM) <b>Dr Jeremiah Chakaya</b> , Kenya Medical Research Institute (KEMRI)
10:30-11:00	<b>Dr Gabrielle Breugelmans</b> , EDCTP <i>Plans and Progress towards EDCTP2</i>
11:00-11:15	Coffee and tea break
11:15-12:00	<b>Keynote address</b> <b>Professor Gavin Churchyard</b> , Aurum Institute
12:00-12:15	<b>Diagnostics</b> <b>Dr Catharina Boehme</b> , Foundation for Innovative New Diagnostics (FIND)
12:15-13:30	<b>Discussion and recommendations</b> Partnerships: Panel Discussion on Diagnostics <ul style="list-style-type: none"><li>• <b>Dr Catharina Boehme</b>, FIND</li><li>• <b>Dr Jim Gallarda</b>, Bill &amp; Melinda Gates Foundation, TB Diagnostics</li></ul>
13:30-14:15	Lunch
14:15-14:30	<b>Global vaccine portfolio</b> <b>Professor Stefan Kaufmann</b> , Max Planck Institute for Infection Biology
14:30-16:00	<b>Discussion and recommendations</b> Partnerships: Panel Discussion on Global Vaccine Portfolio <ul style="list-style-type: none"><li>• <b>Ms Shiva Dustdar</b>, European Investment Bank (EIB)</li><li>• <b>Dr Hannu Lång</b>, European Commission (EC)</li></ul>
16:00-16:15	Coffee and tea break
16:15-16:30	<b>Closing remarks, Day 1 - Chairpersons</b>



## Tuesday 29 October 2013

09:00-09:15	Registration
09:15-09:30	<b>Introduction Day 2 - Chairpersons</b> <b>Professor Hazel Dockrell</b> , LSHTM <b>Dr Jeremiah Chakaya</b> , KEMRI
09:30-09:45	<b>Treatment I: Global drugs portfolio</b> <b>Dr Richard Hafner</b> , National Institutes of Health/National Institute of Allergy and Infectious Diseases, NIH/NIAID
09:45-10:45	<b>Discussion and recommendations</b>
10:45-11:00	Coffee and tea break
11:00-11:30	<b>Treatment II: Clinical management of tuberculosis and mycobacterial infections</b> <b>Tuberculosis: Professor Andreas Diacon</b> , Task Applied Science <b>Leprosy: Professor Diana Lockwood</b> , London School of Hygiene and Tropical Medicine (LSHTM) <b>Buruli Ulcer: Dr Mark Wansbrough-Jones</b> , St George's, University of London (SGUL)
11:30-13:00	<b>Discussion and recommendations</b> Partnerships: Panel Discussion on Treatment I and II: <ul style="list-style-type: none"> <li>• <b>Dr Carl Mendel</b>, Global Alliance for TB Drug Development</li> <li>• <b>Dr Perry Mohammed</b>, Janssen Pharmaceuticals</li> <li>• <b>Dr Dorothy Yeboah-Manu</b>, Noguchi Memorial Institute for Medical Research (NMIMR)</li> </ul>
13:00-13:45	Lunch
13:45-14:00	<b>Control and implementation research</b> <b>Dr Christian Lienhardt</b> , WHO Global TB Programme
14:00-15:30	<b>Discussion and recommendations</b> Partnerships: Control and implementation research <ul style="list-style-type: none"> <li>• <b>Dr Zaza Tsereteli</b>, Barents TB Programme Coordinator at BEAC</li> <li>• <b>Dr Joseph Kawuma</b>, WHO Technical Advisory Group (TAG) on leprosy control</li> </ul>
15:30-15:45	Coffee and tea break
15:45-16:00	<b>Summary and recap of recommendations - Chairpersons</b>
16:00-16:15	<b>Closing remarks</b> <b>Professor Charles Mgone</b> , EDCTP Executive Director <b>Professor Patrice Debré</b> , EDCTP General Assembly representative for France

## Speaker Biographies

### Chairpersons



**Professor Hazel Dockrell** is Professor of Immunology and Special Advisor on Overseas Programmes at the London School of Hygiene & Tropical Medicine, where she is also the Deputy Director of the Tuberculosis Centre. Her research interests include the development of biomarkers for use in TB vaccine trials, immune signatures induced by BCG vaccination in different geographical settings, and how immunity to *Mycobacterium tuberculosis* is modulated by TB therapy, and by diabetes. She is a member of a number of international research consortia and also involved in capacity strengthening activities, particularly in Africa.



**Dr Jeremiah Chakaya** is a holder of an MBChB and M.Med degrees from the University of Nairobi and a post graduate diploma in Thoracic Medicine from the University of London. He has been working with the KEMRI at the Center for Respiratory Diseases Research since 1992 working mainly on TB in people living with HIV. Between 2003 and 2006 he served as the TB program manager for Kenya. He has been engaged in global TB care and control through the Global TB Program of WHO where he served as the chair of the Strategic and Technical Advisory Group - TB for six years (2008 -2013) and the Stop TB Partnership where he served as the chair of the DOTS Expansion Working Group and the Vice Chair of the Stop TB Partnership Coordinating Board. He was a core member of the TB Research Movement of the Stop TB Partnership.

### Keynote address speaker



**Professor Gavin Churchyard** is the Chief Executive Officer of the Aurum Institute, a not-for-profit, public benefit organization that focuses on TB and HIV technical support and research. Professor Churchyard is an Honorary Professor at the University of Witwatersrand, University of Cape Town and at the London School of Hygiene and Tropical medicine. He is the Chair of the WHO/TDR Disease Reference Group for TB, Leprosy and Buruli Ulcer (2009-2013) and a member of the WHO Stop TB Research movement, both of which set global research priorities for TB. Professor Churchyard is the Chair of the WHO Task Force for developing a policy framework for new TB drugs, a member of the WHO Strategic Technical Advisory Group for TB, and a member of the WHO expert committees for TB preventive therapy, TB screening and Xpert MTB/RIF. Professor Churchyard has published widely in the areas of TB and HIV treatment and prevention.

## Session speakers



**Dr Catharina Boehme** in her previous roles at FIND, as Chief Medical Officer and Head of the TB, was responsible for clinical evaluation of new tools for diagnosis for TB, malaria and neglected diseases. Catharina managed the R&D projects for several new point of care technologies and molecular diagnostic approaches requiring close interaction with the diagnostics industry, academia and WHO. Catharina has an extensive background in clinical evaluation and has managed over 30 early-stage trials, 5 late-phase large-scale trials, including for 5 diagnostic tools recently endorsed by WHO. She played a key role in FIND's Xpert MTB/RIF feasibility, evaluation and implementation studies in 12 high-burden countries. Prior, she worked as programme coordinator for the Department of Infectious and Tropical Diseases in Munich, and established a TB research unit at Mbeya Medical Research Program in Tanzania.

---



**Professor Stefan Kaufmann** is a founding director of the Max Planck Institute for Infection Biology, Berlin. Professor for microbiology & immunology, Charité, Berlin. Doctor Honoris Causa from Université de la Méditerranée. Past President of German Society for Immunology, European Federation of Immunological Societies and International Union of Immunological Societies. Scientific interests: immunity to tuberculosis and rational vaccine and biomarker design. Co-Developer of a recombinant TB-vaccine candidate in a phase II-clinical trial. Alternate Board Member of GAVI Alliance. Initiated the global Day of Immunology to raise public awareness. Numerous scientific awards. Coordinator of several international and interdisciplinary projects. More than 700 publications. Editor or member of editorial boards of more than 20 international scientific journals. Member of numerous professional societies and academies.

---



**Dr Richard Hafner** is the Branch Chief of the Tuberculosis Clinical Research Branch, NIAID, NIH. Dr. Hafner's clinical training was in Internal Medicine/Adult Infectious Diseases, and he has been involved with HIV/AIDS clinical research since 1985 with a focus on therapies for opportunistic infections and tuberculosis.

---




**Professor Andreas Diacon**, MD, PhD, is Professor at Stellenbosch University's DST/NRF Centre of Excellence for Biomedical TB Research and Director of Task Applied Science. He is the clinical investigator and microbiology laboratory coordinator for clinical trials with antituberculosis agents. Dr Diacon's main research interests are novel antituberculosis agents and regimens, including laboratory techniques and clinical methods for the evaluation of those. He is also a consultant for Pulmonology and Intensive Care at Tygerberg Academic Hospital, Cape Town.



**Professor Diana Lockwood** is an infectious disease physician (London School of Hygiene & Tropical Medicine) and leprologist (Hospital for Tropical Diseases). She trained in clinical medicine and laboratory science and worked in Africa, India and the United Kingdom. Her work focuses on improving the outcome of leprosy patients with nerve damage. Professor Lockwood's research programme has five main areas, the pathogenesis of leprosy reactions, looking at the molecular effects of treatment on inflammation in leprosy, improving treatment for reactions, neuropathic pain and the interaction between HIV and *M. leprae*. She has over 105 peer-reviewed publications. Further Professor Lockwood has overseas

collaborations with centres in India and Nepal, and ALERT Hospital in Ethiopia and has established a global network on Erythema Nodosum Leprosum (ENLIST) with members in six countries in four continents.

---



**Dr Mark Wansbrough-Jones** is a specialist in infectious diseases in Southwest London. He has worked with colleagues in Ghana doing clinical research with Buruli ulcer patients in the Ashanti Region for more than 15 years. This work has included involvement with clinical trials and studies of the immunopathogenesis of this toxin mediated disease caused by *M. ulcerans*. He is currently chair of the WHO Technical Advisory Group on Buruli ulcer which meets to discuss priorities for research, control and management of this toxin mediated disease caused by *M. ulcerans*.

---



**Dr Christian Lienhardt**, MD, DTM, MSc, PhD, is Senior Research Advisor at the Global TB Programme, World Health Organisation, Geneva (Switzerland). He is an Infectious and Tropical Disease specialist and Clinical Epidemiologist, graduated from the Universities of Strasbourg (France), and London (UK). After several years as a clinician in France, he undertook medical relief and health development work with various NGOs in several countries in the Middle-East and in Africa. He then carried out clinical and epidemiological research on tuberculosis in West Africa (Mali, The Gambia, Senegal) with the UK Medical Research Council (MRC) and

French Institute for Research in Development (IRD), including observational cohort and case-contact studies, multicenter clinical trials, as well as programmatic and operational research studies. He headed the Clinical Trial Division at the International Union Against Tuberculosis and Lung Diseases (The Union) in Paris. He joined in 2009 the Stop TB Partnership at WHO, where he was in charge of the "TB Research Movement". In 2012, he moved to the Global TB Programme where he is in charge of the rational introduction of new TB drugs in high TB burden countries, and advises on several aspects of TB research.

---




## Partnerships and collaborations panel members



patients with CML.

**Dr Jim Gallarda** serves as a Senior Program Officer responsible for TB diagnostic development programs supported by the Bill & Melinda Gates Foundation. He has more than 20 years' experience in developing in vitro diagnostics at Abbott Laboratories & Roche Molecular Systems where he led multiple teams developing immunodiagnostic & PCR systems for HIV-1, HIV-2, HCV, HBV and WNV. Most recently, while at Novartis Pharmaceuticals (in Cambridge MA), Dr. Gallarda led a companion diagnostics program for assays used to assess the effectiveness of tyrosine kinase inhibitors used for treating



**Ms Shiva Dustdar**, Head of RDI Advisory, Advisory Services Department, is currently working at the European Investment Bank (EIB) in Luxembourg, where she is heading the Research, Development and Innovation Advisory Services, a new joint initiative with the European Commission (DG R&I). She has been at the EIB since 2003, first in its Risk Management Directorate, then in its EU Lending Directorate where she was responsible for financing of R&D projects using the Risk Sharing Finance Facility (RSFF).

Before joining the EIB, Shiva worked at Fitch as Director of High Yield where she was responsible for developing the agency's European High Yield rating business. Prior to Fitch, Shiva worked from 1993-1999 at the M&A Advisory of J.P. Morgan in New York and then in its Investment Banking Group in London.

Shiva graduated from Columbia University (NY) in Economics with Magna cum Laude and holds an Executive MBA from London Business School (LBS).



**Dr Hannu Lång** is a Scientific Officer working in the Unit of Infectious Diseases and Public Health of the Health Directorate of DG Research and Innovation of the European Commission. His current responsibilities include Tuberculosis research policy, planning of activities in the field of Tuberculosis research and managing the portfolio of FP7 funded research projects.

Before joining the European Commission he was doing research and teaching Molecular Microbiology as Professor of Microbiology at the University of Helsinki. He received his Ph.D. in Molecular Genetics from the Swedish University of Agricultural Sciences. Before joining the European Commission in 2005 he had a long career in science in Finland, Sweden and Australia, focusing on understanding molecular


mechanisms of bacterial pathogenesis.



As Senior Vice President, Research and Development for the TB Alliance, **Dr Carl Mendel** guides and oversees the organization's research and development activities. Dr. Mendel has more than 15 years of experience in the pharmaceutical industry, with significant research and development expertise in a variety of therapeutic areas, especially in early- and late-stage clinical development. Prior to his position with the TB Alliance, Dr. Mendel most recently served as Chief Medical Officer at Synvista Therapeutics. Prior, Dr. Mendel served in roles of increasing responsibility at Merck and Co., Knoll Pharmaceuticals (a division of BASF Pharma), Aventis Pharmaceuticals, and Sanofi-Aventis. During his career, he has contributed to the successful approvals of numerous pharmaceutical products that have been launched around the world.

Dr. Mendel holds a B.A. degree from Columbia University and an M.D. degree from the University of California, San Diego. He is board certified in Internal Medicine and in Endocrinology and Metabolism. Before joining the pharmaceutical industry, he was Assistant Professor of Medicine at the University of California, San Francisco. Dr. Mendel has authored or co-authored more than 50 articles in leading scientific journals.

---



**Dr Perry Mohammed**, Medical Director of Global Access Programme and Partnerships (GAPP), is responsible for delivering on the Medical Affairs strategy for improving access to Janssen's HIV medications and compounds in the developing world, in strong partnership with the Global R&D, Global Strategic Marketing & Market Access, and regional and local business units. His role also includes the development of partnerships with non-profit, government and non-government organizations all with the aim of facilitation of HIV drug access to the patients who are in need. His current role

encompasses Medical education and clinical trials and compassionate use access of Janssen's HIV compounds.

Having graduated from the University of the West Indies in 1998 with a MBBS degree, he worked in the public health service in Trinidad and Tobago as a junior doctor, gaining experience in internal medicine and emergency care. It was here his passion for HIV as a therapeutic area budded, after treating patients for opportunistic infections and providing palliative care to those who had no access to HIV drugs. He continued his career as a HIV physician in the UK, working in the National Health Service where HIV drug access was not an issue. As a result Perry developed a broad perspective of the medical gaps and unmet needs for HIV drug access in resource limited settings.



**Dr Dorothy Yeboah-Manu** is a microbiologist who heads the Bacteriology Department, Noguchi Memorial Institute for Medical Research, University of Ghana. She is also a Fellow of the Wellcome Trust. Her research activities focus on host-pathogen interactions in *Mycobacterium tuberculosis* and *Mycobacterium ulcerans* infections. The aims of her current TB study are to determine the transmission dynamics of TB, analyse for genomic diversity and gene expression profiles between *Mycobacterium tuberculosis* and *Mycobacterium africanum*. Within Buruli ulcer (BU) she focuses on understanding disease epidemiology, elucidation of biomedical factors underlying healing delay for improved wound care and improvement of diagnostics. Dorothy is a member of the WHO network of laboratories that confirms BU, and works closely with the national control programs for both TB and BU.



**Dr Zaza Tsereteli, MD, MPH**, is Coordinator of the Barents TB Programme, at the Barents Euro-Arctic Council (BEAC). He is an Infectious Disease and Public Health specialist and Epidemiologist, graduated from the Tbilisi State Medical University (Georgia) and Royal Tropical University, (KIT, Amsterdam). He has an extensive experience in heading and supporting projects in the field of HIV/AIDS, TB, Substance Abuse, and Prison Health. During the last 18 years he was actively involved in facilitating collaboration and coordination at international and national level, with local stakeholders,

multi-, bi-lateral organizations and donors. He joined the Norwegian Ministry of Health and Care Services in 2008 and in 2010 was assigned to Coordinate TB Programme at BEAC. Simultaneously, he was an International Technical Advisor for the Expert Group on Prison Health for the Northern Dimension Partnership (NDPHS), providing support to 11 partner countries in the Northern Dimension area. Before this, he worked with UNODC, TF of CBSS, and UNICEF. During his work at Task Force for the Council of Baltic Sea States (TF/CBSS), more than 36 projects in the field of HIV/AIDS and TB were implemented with his direct supervision and technical assistance. He is one of the authors of working program/Strategy for the collaboration in the prevention of HIV within the context of EU/ND initiative, and Oslo Declaration on Prison Health. He is a member of Board of International Association of Providers of AIDS Care (IAPAC) and member of EU HIV/AIDS Think Tank.



**Dr Herman Joseph Ssekamatte Kawuma** is currently employed as Medical Advisor, German Leprosy and TB Relief Association (GLRA/DAHW) in Uganda. He is a member and current Chair of the WHO Technical Advisory Committee (TAG) on Leprosy.

He was a member of the WHO Expert Panel on Leprosy (1997-2000, 2011) and also participated in various WHO forums addressing issues of Leprosy control at Global and Regional levels. He was a member of the Technical Reference Panel of The Leprosy Mission International (TLM) between 2001 and 2005.

He was a Councilor of the International Leprosy Association (ILA) from 1994 to 2008 and is currently ILA Vice President for Africa. Between 1983 and 2002 he was Medical

Superintendent, Clinician and Trainer at Uganda's national referral and training centre





for leprosy, St. Francis Hospital, Buluba, Uganda. For part of that time he was also Deputy Manager of the Uganda National TB/Leprosy Programme.

---